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he toxic effect of cholera toxin (CT) on target cells is
caused by its A1 chain. This polypeptide is released
from the holotoxin and unfolded in the lumen of the
ER by the action of protein disulﬁde isomerase (PDI), before
being retrotranslocated into the cytosol. The polypeptide
is initially unfolded by binding to the reduced form of
PDI. We show that upon oxidation of the COOH-terminal
disulﬁde bond in PDI by the enzyme Ero1, the A1 chain is
 
released. Both yeast Ero1 and the mammalian Ero1
 
 
 
 isoform
T
 
are active in this reaction. Ero1 has a preference for the
PDI–toxin complex. We further show that the complex is
transferred to a protein at the lumenal side of the ER
membrane, where the unfolded toxin is released from PDI
by the action of Ero1. Taken together, our results identify
Ero1 as the enzyme mediating the release of unfolded CT
from PDI and characterize an additional step in retrotrans-
location of the toxin.
 
Introduction
 
The bacterium 
 
Vibrio cholerae
 
 produces cholera toxin (CT)*
 
which affects mammalian intestinal epithelial cells by causing
salt and water secretion resulting in diarrhea (Sears and
Kaper, 1996). CT consists of a ring of five B subunits and a
single A subunit. The A subunit is cleaved into the A1 catalytic
domain and the A2 domain upon secretion of the toxin by
 
V. cholerae.
 
 The A1 and A2 fragments are connected by a
disulfide bridge and by noncovalent interactions. The holotoxin
is endocytosed and traffics in a retrograde manner along the
secretory pathway to the lumen of the ER (Lencer et al.,
1999). In this compartment, the disulfide bridge of the A
subunit is reduced, and the A1 chain is released from the rest of
the toxin and translocated to the cytosol. Based on coimmuno-
precipitation and ribosome inhibition experiments, it seems
that the A1 peptide is translocated through the Sec61p
channel (Schmitz et al., 2000), the same channel used to
translocate secretory, lumenal, and membrane proteins from
the cytosol to the ER lumen (for review see Matlack et al.,
1998). Although the signal transduction pathway induced
by the A1 chain in the cytosol is well characterized, much
less is known about the mechanism by which the A1 peptide
is transported from the ER lumen to the cytosol, a process
termed retrotranslocation (for review see Tsai et al., 2002).
Unfolding of the A1 peptide likely represents the first step
in retrotranslocation of the toxin. Using a biochemical fraction-
ation approach that made no assumptions about the nature
of this unfolding activity, we previously identified the ER
oxido-reductase protein disulfide isomerase (PDI) as the major
activity that disassembles the toxin and unfolds the A1 chain
(Tsai et al., 2001). More detailed analysis demonstrated that
PDI acts as a redox-dependent chaperone; in its reduced
state, PDI binds and unfolds the toxin, whereas in its oxidized
state, PDI releases it. Release of the A1 chain from PDI
upon oxidation must occur prior to its retrotranslocation
across the ER membrane. When oxidation is induced with
oxidized glutathione (GSSG), an unphysiologically high
concentration was required to induce release (Tsai et al.,
2001). Therefore, we hypothesized that this process must
normally be catalyzed by an enzyme, i.e., an oxidase of PDI.
Here we identify the enzyme responsible for the release
reaction, provide a mechanism for the release, and describe
an additional step in retrotranslocation of the toxin. Our
data demonstrate that the ER oxidase Ero1 is responsible for
inducing release of the toxin from reduced PDI through
oxidation of the COOH-terminal disulfide bond in PDI.
Furthermore, we show that the complex of PDI and unfolded
toxin is targeted to a protein on the lumenal side of the ER
membrane. Subsequently, the toxin is released from PDI by
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the action of Ero1, presumably committing the toxin to ret-
rotranslocation across the ER membrane.
 
Results and discussion
 
An ER activity induces toxin release from PDI
 
To identify an activity that caused the unfolding of purified
A subunit of CT, we have previously used an ER extract
from dog pancreatic microsomes that was obtained by the
addition of a low concentration of detergent, and contained
lumenal and some membrane proteins. The ER extract ren-
dered the A and A1 peptides sensitive to trypsin digestion
under reducing conditions (1 mM reduced glutathione,
GSH; Fig. 1 A, lane 6; Tsai et al., 2001). BSA did not show
this effect (Fig. 1 A, lane 2), indicating that a protein in the
ER extract induces unfolding of the toxin. The protein was
subsequently identified as PDI; indeed, incubation of puri-
fied PDI with toxin under reducing conditions similarly
caused the A1 chain to be sensitive to trypsin digestion (Fig.
1 A, compare lane 4 with lane 2; Tsai et al., 2001).
To probe the interaction between the toxin A chain and
PDI, we developed a crosslinking assay (Tsai et al., 2001).
Briefly, purified PDI or ER extract were incubated with the
A subunit of CT under reducing conditions, followed by ad-
dition of a carbodiimide to induce crosslinks between car-
boxyl and amino groups of the two proteins. This complex is
visualized as a higher molecular mass band in SDS-PAGE
after immunoblotting with an antibody that recognizes the
A subunit of CT. It should be noted that in both the trypsin
digestion and crosslinking assays, PDI is in an 
 
 
 
40-fold mo-
lar excess over the toxin.
Using this assay, we found that a PDI–A chain complex
can be seen with purified PDI, but not with ER extract or
BSA (Fig. 1 B, compare lane 3 with lanes 2 and 1; Tsai et al.,
2001). Together with the unfolding assay, these results sug-
gest that the toxin must be undergoing cycles of binding and
release from PDI when incubated with ER extract, thereby
preventing the formation of a stable PDI–toxin complex
that can be captured by the crosslinker.
To directly test the possibility that a release activity exists
in the ER extract, we first generated the PDI–A chain com-
plex by incubating PDI and purified toxin together under
reducing conditions. BSA or ER extract were then added to
the preformed complex to induce toxin release, and the dis-
sociation of the complex was probed with a bifunctional car-
bodiimide crosslinker. Indeed, addition of ER extract, but
not BSA, resulted in loss of the crosslinked product (Fig. 1
C, compare lane 2 with lane 1). This result confirms the
presence of an activity in the ER extract that induces the re-
lease of the A1 chain from PDI. Because addition of high
concentrations of the oxidant GSSG can also induce toxin
release (Tsai et al., 2001), the release activity is likely to be
an oxidase of PDI.
 
Ero1 induces the release of unfolded toxin 
from reduced PDI 
 
Using two different genetic screens in 
 
Saccharomyces cerevi-
siae
 
, Ero1 was identified as an enzyme that functions as a
PDI oxidase in the ER lumen (Frand and Kaiser, 1998,
1999; Pollard et al., 1998). Ero1 contains the cofactor FAD
and may use molecular oxygen to reoxidize itself (Tu et al.,
2000). We asked whether the mammalian homologue of
Figure 1. An ER activity induces release of the A1 chain from PDI. 
(A) Isolated A subunit (70 nM) was incubated with either BSA 
(3  M), purified mammalian PDI (3  M), or ER extract (3 mg/ml) in 
GSH (1 mM). Where indicated, trypsin (100  g/ml) was added. 
Samples were analyzed by nonreducing SDS-PAGE and immuno-
blotting with a CT antibody. The positions of the proteolytically 
cleaved A subunit (containing A1 and A2 chains linked by a disulfide 
bond) and of the A1 chain are indicated. (B) Isolated A subunit 
(70 nM) was incubated with either BSA (3  M), ER extract (3 mg/ml) 
or purified PDI (3  M) in GSH (1 mM). A carbodiimide crosslinker 
(EDAC) was then added. Samples were analyzed as in (A). PDI-A 
represents a crosslinked product between PDI and the A subunit. 
* indicates an unidentified band. (C) Isolated A subunit (70 nM) was 
first incubated with purified PDI (3  M) in GSH (1 mM), followed 
by addition of either BSA (3  M) or ER extract (3 mg/ml). Samples 
were analyzed as in (B). 
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Ero1 may be responsible for the release activity in the ER ex-
tract. In mammals, two different Ero1 isoforms have been
identified, Ero1
 
 
 
 (Cabibbo et al., 2000) and Ero1
 
 
 
 (Pagani
et al., 2000). To test whether both isoforms are present in
dog microsomes, three different mammalian Ero1 antibod-
ies were used, one that recognizes both mammalian Ero1
isoforms (
 
 
 
/
 
 
 
, antibody 194), one that only recognizes the
Ero1
 
 
 
 isoform, and one that only recognizes the Ero1
 
 
Figure 2. Ero1 induces the release of the A1 peptide from reduced PDI. (A) Protein from five equivalents of dog pancreatic microsomes 
were treated with or without endo H and analyzed by SDS-PAGE followed by immunoblotting with antibodies to Ero1 /  (lanes 1 and 2), 
Ero1  (lanes 3 and 4), or Ero1  (lanes 5 and 6). Purified mammalian Ero1  (1  g), analyzed in the Coomassie gel (lane 7), was tested with 
antibodies to Ero1 / , Ero1 , or Ero1  (lanes 8–10). x represents an uncharacterized glycosylated form of Ero1 . (B) ER extract or Ero1-
depleted extract (depleted by incubation with either antibody 193 or 194) were analyzed by immunoblotting with antibodies to Ero1 /  
(antibody 194, lanes 1–3), Ero1  (lanes 4–6), or Ero1  (lanes 7–9). Lanes 10–14 show the results of release assays. Isolated A subunit (70 nM) 
and PDI (3  M) were incubated in GSH (1 mM) followed by addition of BSA (2 mg/ml), ER extract (2 mg/ml), Ero1-depleted extract (depleted 
by antibody 193 or 194), or GSSG (30 mM; lanes 10–14). The samples were analyzed as in Fig. 1 B. (C) Purified mammalian Ero1  (0.3  M 
or 3  M) was added to the PDI–toxin complex and analyzed as in Fig. 1 B (lanes 1–3). Purified yeast Ero1 (Coomassie gel, lane 4) was added 
(0.3  M or 1.5  M) to the toxin-PDI complex and the samples were analyzed as in Fig. 1 B (lanes 5–7). 
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isoform. The Ero1
 
 
 
/
 
 
 
 antibody recognized three distinct
bands in the microsomes, with the top band corresponding
to Ero1
 
 
 
, the middle band corresponding to Ero1
 
 
 
, and the
bottom band corresponding possibly to a novel Ero1 iso-
form or a degradation product (Fig. 2 A, lane 1). The slower
mobility of Ero1
 
 
 
 compared to Ero1
 
 
 
 is consistent with
previous results (Pagani et al., 2000). Treatment of mi-
crosomes with endoglycosidase H (Endo H) increased the
mobility of all three bands, confirming previous findings
that Ero1
 
 
 
 and Ero1
 
 
 
 are glycoproteins (Fig. 2 A, lane 2;
Pagani et al., 2000). The Ero1
 
 
 
- and Ero1
 
 
 
-specific anti-
bodies each recognized only one Endo H–sensitive band in
the microsomes (Fig. 2 A, lanes 3 and 5, respectively), which
correspond to the positions of the top and middle bands
identified using the Ero1
 
 
 
/
 
 
 
 antibody, respectively. An ad-
ditional Endo H–resistant band was observed using the
Ero1
 
 
 
-specific antibody (Fig. 2 A, lane 4), which may repre-
sent an uncharacterized glycosylated form of Ero1
 
 
 
.
To test the specificity of the antibodies, we expressed and
purified mammalian Ero1
 
 
 
 from yeast cells (Fig. 2 A, lane
7). Both the Ero1
 
 
 
/
 
 
 
 and Ero1
 
 
 
-specific antibodies recog-
nized the purified Ero1
 
 
 
 protein, whereas the Ero1
 
 
 
-spe-
cific antibody did not (Fig. 2 A, lanes 8–10). We were un-
able to purify the mammalian Ero1
 
 
 
 protein from yeast.
We next used the antibodies to directly test whether the
release activity observed in the crude ER extract can be at-
tributed to Ero1. Both isoforms of Ero1 were present in the
extract obtained with low detergent concentrations. To de-
plete Ero1
 
 
 
 and Ero1
 
 
 
 we used two different antibodies di-
rected against both proteins (antibodies 193 and 194; Fig. 2
B, compare lanes 2 and 3 with lane 1; lanes 5 and 6 with
lane 4; and lanes 8 and 9 with lane 7). Although addition of
ER extract to the preformed PDI-toxin complex induced
loss of the crosslinked product, addition of either of the two
Ero1-depleted extracts did not (Fig. 2 B, compare lane 11
with lanes 12 and 13). In fact, with one antibody the
crosslinked band was more intense than in the control, sug-
gesting that in the absence of Ero1, the extract is more re-
ducing than 1 mM GSH, perhaps due to the presence of a
PDI-reductase. These results demonstrate that Ero1 is re-
quired for the release activity. As previously reported, addi-
tion of a high concentration of GSSG (30 mM) also resulted
in the loss of the crosslinked product (Fig. 2 B, compare lane
14 with lane 10; Tsai et al., 2001).
Figure 3. Release activity is present in Ero1 -containing fractions. (A) The protein in an ER extract was bound to a Q-Sepharose column and 
eluted with a continuous salt gradient. Fractions were analyzed for its Ero1 content by SDS-PAGE and immunoblotting with antibodies that 
either recognize both Ero1 isoforms (top), Ero1  only (middle), or Ero1  only (bottom). (B) The fractions were tested for their ability to induce 
toxin release, as described in Fig. 1 B. 
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We next asked whether Ero1 is sufficient for stimulating
toxin release. Addition of purified Ero1
 
 
 
, either in sub-
stoichiometric (1:10) or stoichiometric (1:1) ratio to PDI, to
the preformed PDI-toxin complex resulted in the disappear-
ance of the crosslinked product (Fig. 2 C, compare lanes 2
and 3 with lane 1). The same result was obtained upon addi-
tion of purified yeast Ero1 (Fig. 2 C, lane 4), either in sub-
stoichiometric (1:10) or near-stoichiometric (1:2) ratio to
PDI (Fig. 2 C, compare lanes 6 and 7 with lane 5). We con-
clude that Ero1 is both necessary and sufficient to induce re-
lease of the toxin from PDI.
We also separated the ER extract on an ion exchange col-
umn (Q-Sepharose) and tested each fraction for its content of
Ero1 and its activity to release the toxin from reduced PDI.
Two pools of Ero1 were found using the Ero1
 
 
 
/
 
 
 
 antibody,
one pool corresponding to fractions 5–9 (Fig. 3 A, top, lanes
1–5), identified as Ero1
 
 
 
 (Fig. 3 A, middle, lanes 1–5), and
another corresponding to fractions 17–21 (Fig. 3 A, top, lanes
13–17), identified as Ero1
 
 
 
 (Fig. 3 A, bottom, lanes 13–17).
Only fractions 5–9 were active in the release assay (Fig. 3 B,
compare lanes 2–6 with lanes 14–18). These data confirm
that Ero1
 
 
 
 is able to induce toxin release from PDI and raise
the possibility that Ero1
 
 
 
 may be inactive in this assay. Inter-
estingly, based on the theoretical pI values of the two iso-
forms, Ero1
 
 
 
 is expected to elute before Ero1
 
 
 
, in contrast to
the observation. It seems therefore likely that interactions
with other proteins alter the properties of the isoforms. A
novel ER protein, called Erp44, interacts with both Ero1 iso-
forms and is therefore unlikely to be responsible for the
anomalous behavior of the two proteins (Anelli et al., 2002).
 
Ero1 oxidizes the COOH-terminal disulfide bond in 
PDI and acts preferentially on the PDI–toxin complex
 
To demonstrate that the mechanism of Ero1-mediated toxin
release is due to oxidation of PDI, we designed an assay that
allows us to examine PDI’s oxidation state. Maleimide-
PEG5000 is a chemical of 
 
 
 
5,000 daltons that allows the
modification of thiol groups in cysteines, and thereby signif-
icantly increases the size of the protein. The mobility shift is
analyzed by SDS-PAGE followed by immunoblotting with
an antibody directed against the modified protein. When
PDI was fully reduced by 100 mM DTT and treated with
maleimide-PEG5000, a dramatic upward mobility shift of
PDI was seen (Fig. 4 A, compare lane 1 with lane 6). Under
this condition, all six cysteines in PDI are expected to be in
the reduced state and should therefore be modified. When
PDI was incubated in the presence of a high concentration
of the GSSG (100 mM), a much smaller upward mobility
shift was observed (Fig. 4 A, compare lane 5 with lane 6).
Under these conditions, only the two noncatalytic cysteines
can be modified, whereas the cysteines within the two
thioredoxin domains of PDI, each characterized by a CxxC
motif, are expected to form disulfide bonds.
Incubation of PDI with GSH (1 mM) followed by malei-
mide-PEG5000 treatment resulted in an upward mobility shift
similar to the mobility shift induced with DTT treatment
(Fig. 4 A, compare lane 2 with lane 1), although some degree
of smearing was consistently observed. Importantly, addition
of stoichiometric amounts of mammalian Ero1
 
 
 
 produced an
upward mobility shift of PDI that was intermediate to the
 
shifts seen when two or six cysteines in PDI were modified
(Fig. 4 A, compare lane 4 with lane 2). Similar results were ob-
served using near-stoichiometric amounts of yeast Ero1 (Fig. 4
B, compare lane 5 with lane 3). The simplest interpretation of
this data is that Ero1 oxidizes only one of the two disulfide
bonds in PDI, leaving four cysteines available for modifica-
tion. The ability of Ero1 to oxidize PDI in the presence of 1
mM GSH is consistent with previous findings that yeast Ero1
can oxidize PDI even in 3 mM GSH (Tu et al., 2000).
To further establish that Ero1 can oxidize only one of
PDI’s two disulfide bonds, a tenfold excess of yeast Ero1 was
added to reduced PDI. Again, only one of PDI’s two disul-
fide bonds was oxidized (Fig. 4 C, compare lane 2 with lane
1). To determine whether Ero1 oxidizes the disulfide bond
in the NH
 
2
 
- or COOH-terminal thioredoxin domain of
PDI, we used purified mutants of yeast PDI in which the
CxxC motif in either the NH
 
2
 
- or COOH-terminal domain
is mutated to AxxA (PDI
 
AxxA-CxxC
 
 and PDI
 
CxxC-AxxA,
 
, respec-
tively; Fig. 4 D, lanes 1 and 2). Using a tenfold excess of
yeast Ero1 over PDI, we found that only the PDI
 
AxxA-CxxC
 
mutant was oxidized by Ero1 (Fig. 4 D, compare lane 6 with
lane 8). Thus, Ero1 oxidizes only the disulfide bond in the
carboxy-terminal thioredoxin domain.
Interestingly, addition of substoichiometric amounts of
Ero1
 
 
 
 or yeast Ero1 did not alter the mobility shift of PDI
(Fig. 4, A, compare lane 3 with lane 2, B, compare lane 4
with lane 3), indicating that this amount of Ero1 is insuffi-
cient to oxidize the bulk of PDI. However, under the same
conditions, both Ero1
 
 
 
 and yeast Ero1 were able to fully in-
duce release of toxin from PDI (Fig. 2 C, compare lane 2
with lane 1; compare lane 6 with lane 5). One explanation is
that Ero1 preferentially binds to and oxidizes the PDI–toxin
complex. Because the concentration of the toxin is much
lower than that of PDI, oxidation of complexed PDI would
not be visible in the modification assay. Indeed, when we
added a stoichiometric concentration of toxin with respect
to PDI, a mobility shift of PDI could be observed even at
low concentrations of Ero1 (Fig. 4 E, compare lane 6 with
lane 2). The band that runs between the ones corresponding
to four and six free thiol groups may perhaps be caused by
the formation of a mixed disulfide bond with either the
toxin or GSH. Taken together, these data support the idea
that Ero1 preferentially acts on the PDI-toxin complex.
 
PDI-unfolded toxin is transferred to the ER membrane
 
During retrotranslocation of the A1 chain, the unfolded A1
peptide must be targeted to the ER membrane and ulti-
mately engage the translocation channel in order to be trans-
ported to the cytosol. We designed an assay to examine
transfer of the unfolded A1 chain to the ER membrane, a
process that likely mimics an intermediate step in retrotrans-
location of the toxin. Purified A subunit of the toxin was ini-
tially incubated with ER extract under reducing conditions
to stimulate toxin unfolding. Then proteoliposomes were
added which were generated by dissolving microsomes in
detergent followed by removal of the detergent with hydro-
phobic beads. These proteoliposomes contain essentially all
ER membrane proteins with their orientations randomized.
This should allow the PDI–toxin complex to interact with
lumenal domains of membrane proteins. To assay for bind- 
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ing of the PDI–toxin complex, the proteoliposomes were
sedimented and the pellet and supernatant fractions ana-
lyzed by immunoblotting with toxin antibodies.
Although addition of ER extract or proteoliposomes alone
did not induce transfer of the A1 peptide to the pellet frac-
tion, addition of ER extract followed by proteoliposomes
Figure 4. Ero1 oxidizes the COOH-terminal disulfide bond in PDI and acts preferentially on the toxin–PDI complex. (A) Isolated A subunit 
(70 nM) and purified mammalian PDI (3  M) were incubated in the presence of DTT (100 mM), GSSG (100 mM), or GSH (1 mM). Where 
indicated, purified mammalian Ero1  (0.3  M or 3  M) was added. 1/10 of the sample was TCA precipitated, washed with acetone, and 
treated with maleimide-PEG5000. The samples were subsequently analyzed by nonreducing SDS-PAGE followed by immunoblotting with an 
antibody against PDI. Arrows point to the number of cysteines in PDI modified with maleimide-PEG5000 (-SH-MP). (B) As in A except that 
purified yeast Ero1(0.3  M or 1.5  M) was used. (C) As in B except that 30  M yeast Ero1 was added. (D) As in C except that 3  M yeast 
mutant PDICxxC-AxxA or PDIAxxA-CxxC were used. (E) As in B except 70 nM or 3  M of isolated A subunit were incubated with PDI (3  M). 
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caused a fraction of the A1 peptide (30%) to be transferred
to the pellet (Fig. 5 A, compare lanes 1 and 3 with lane 5).
Neither liposomes lacking proteins nor intact microsomes
(which do not have the lumenal domains of membrane pro-
teins exposed) stimulated toxin transfer (Fig. 5 A, compare
lanes 7 and 9 with lane 11), indicating that the unfolded A1
chain does not bind to lipids or irrelevant proteins. This is
supported by the fact that proteoliposomes generated from a
Figure 5. PDI-unfolded A1 peptide is transferred to the ER membrane. (A) Isolated A subunit (70 nM) was incubated in the presence of GSH 
(1 mM) with ER extract, proteoliposomes, or ER extract followed by proteoliposomes (lanes 1–6). After sedimentation, the proteoliposome-bound 
toxin in the pellet fraction and the unbound fraction in the supernatant were analyzed by nonreducing SDS-PAGE followed by immunoblotting. 
Controls were performed with either native microsomes (lanes 9 and 10), liposomes lacking proteins (lanes 7 and 8), or proteoliposomes 
generated from a proteinase K-treated detergent extract (lanes 15 and 16). (B) Isolated A subunit (70 nM) was incubated with either BSA, ER 
extract, or 6M urea (lanes 1–6). Where indicated, trypsin (100  g/ml) was added. Samples were analyzed as in A. In lanes 7–10, isolated A 
subunit (70 nM) was incubated with either ER extract or 6M urea (followed by addition of proteoliposomes. Samples were analyzed as in A. 
(C) In lanes 1–3, ER extract or PDI-depleted extract were analyzed by immunoblotting with PDI antibodies. In lanes 4–7, isolated A subunit 
(70 nM) was incubated with these extracts, followed by the addition of proteoliposomes and the samples were separated into pellet and 
supernatant fractions. In lanes 8–11, isolated A subunit (70 nM) was incubated with purified PDI or BSA followed by addition of proteoliposomes. 
(D) As in Fig. 1 C, except BSA, wild-type mammalian proteoliposomes, wild-type yeast proteoliposomes, or yeast mutant ero1–1 proteoliposomes 
were added to the preformed PDI–toxin complex.214 The Journal of Cell Biology | Volume 159, Number 2, 2002
proteinase K-treated detergent extract did not show binding
activity (Fig. 5 A, compare lanes 15 and 13). Thus, it ap-
pears that the unfolded A1 peptide specifically binds to a
protein at the lumenal side of the ER membrane. An un-
folded state of the A1 peptide is insufficient to achieve bind-
ing to the ER membrane as demonstrated with A chains that
were chemically unfolded with urea. The urea-treated A and
A1 peptides were as sensitive to trypsin treatment as the A1
peptide unfolded with an ER extract (Fig. 5 B, compare
lanes 6 and 4 with lane 2), but they did not bind to proteoli-
posomes (Fig. 5 B, compare lane 7 with lane 9). Thus, it ap-
pears that the formation of a PDI–toxin complex is neces-
sary for transfer to the ER membrane, perhaps because PDI
specifically interacts with a membrane protein. To further
test this point, we asked whether PDI is required for the
transfer reaction by using ER extract immunodepleted of
PDI (Fig. 5 C, compare lane 3 with lane 2). Indeed, the
PDI-depleted extract did not support toxin transfer to the
membrane (Fig. 5 C, compare lane 6 with lane 4). Further-
more, purified PDI was competent in inducing transfer of
the A1 chain to proteoliposomes (Fig. 5 C, compare lane 10
with lane 8). Therefore, PDI is both necessary and sufficient
for the transfer of unfolded A1 peptide to the ER mem-
brane. These experiments also show that Ero1 in the ER lu-
men is not required. About 10% of total Ero1 is found in
the proteoliposomes, but this population also does not seem
to be required for the transfer of the toxin to the ER mem-
brane, because proteoliposomes generated from microsomes
of the yeast ero1-1 mutant bound the PDI–toxin complex
with unreduced efficiency (unpublished data). However, the
mutant proteoliposomes were inactive in releasing the toxin
from PDI, in contrast to wild-type vesicles (Fig. 5 D, com-
pare lane 4 with lanes 2 and 3). Thus, these results indicate
that the complex of toxin and PDI is first transferred to the
ER membrane and then dissociated by the action of Ero1.
Role of PDI-Ero1 unfolding in retrotranslocation of CT
Based on our findings, we propose the following model for
retrotranslocation of CT. Upon reaching the ER lumen, the
A1 chain is released from the rest of the toxin and unfolded
by PDI. The reduced form of PDI binds to the A1 chain
and unfolds it. We assume that the PDI-A1 complex is then
targeted to the ER membrane because the A1 chain alone,
even when unfolded, does not have a high affinity for the
ER membrane. Because PDI, but not Ero1, is required for
membrane targeting of the toxin, it appears that the PDI–
toxin complex binds to a protein at the lumenal side of the
ER membrane via PDI. Our results suggest that the next
step is oxidation of PDI by Ero1 and release of the toxin
from PDI at the membrane. Because the A1 chain refolds
when it is released from PDI into buffer, we assume that the
unfolded toxin is transferred directly into the translocation
channel. This would be possible if either the PDI-interacting
protein at the ER membrane or Ero1 were associated with
the channel. In this connection it will be interesting to iden-
tify the proteins that appear to be associated with the two
isoforms of Ero1 in the ER extract.
Although we have seen release of the toxin from PDI with
both Ero1 in the ER detergent extract and with Ero1 present
in reconstituted proteoliposomes, in vivo the active species is
likely to be membrane-bound Ero1. Because Ero1 lacks a
transmembrane domain and a K/HDEL sequence at its
COOH terminus, it may be kept in the ER by an associa-
tion with a membrane protein. Its appearance in the ER ex-
tract may be caused by disruption of this interaction by even
low concentrations of detergent. Our results show that the
 -isoform of Ero1 is capable of releasing the A1 chain from
PDI, whereas fractions containing Ero1  were inactive. This
raises the possibility that Ero1  may serve a different func-
tion in the cell than Ero1 , perhaps in the refolding of mis-
folded ER proteins, but we cannot exclude the possibility
that Ero1  was inactivated during sample preparation.
Our data show that Ero1 only oxidizes the COOH-termi-
nal disulfide bond in PDI to cause toxin release. This find-
ing is consistent with previous results showing that the
COOH-terminal thioredoxin domain plays a more critical
role than its NH2-terminal counterpart during the in vitro
refolding of carboxypeptidase Y (CPY), and of bovine pan-
creatic trypsin inhibitor (Westphal et al., 1999). In addition,
the NH2-terminal thioredoxin domain does not appear to
play a role in the PDI-mediated retrotranslocation of mis-
folded prepro-  factor (Gillece et al., 1999). However, in
vivo the NH2-terminal thioredoxin domain was found to
play a more important role than the COOH-terminal do-
main in the folding of CPY (Holst et al., 1997). The reasons
for the differences between the in vitro and in vivo results re-
main to be clarified. Our results also indicate that Ero1 is
more efficient in oxidizing toxin-associated PDI compared
to free PDI. Although the molecular mechanism for this
preference is unclear, it could prevent futile redox cycles of
PDI in the absence of substrate.
Whether the PDI-Ero1–driven unfolding mechanism is
used to translocate other substrates, such as misfolded ER
proteins, remains to be explored. However, PDI and PDI-
related proteins have been implicated in the retrotransloca-
tion of misfolded ER substrates (Gillece et al., 1999; Wang
and Chang, 1999), suggesting that the proposed pathway
may be general.
Materials and methods
Antibodies
The A subunit of CT was purchased from Calbiochem and mammalian PDI
from Takara. Antibodies against different proteins were kind gifts from the
following sources: mammalian PDI from H. Ploegh (Harvard Medical
School), Ero1  and   from H. Ploegh and C. Kaiser (Massachusetts Institute
of Technology, Cambridge, MA), Ero1  from A. Benham (University of
Durham, UK), A subunit of CT from W. Lencer (Harvard Medical School),
and yeast PDI from T. Stevens (University of Orgeon, Eugene, OR). Anti-
bodies against mammalian Ero1  were generated using a peptide contain-
ing the sequence SIKDCHVEPC with the NH2 terminus acetylated. 
Purification of yeast PDI mutants
Plasmids expressing mutant yeast PDICxxC-AxxA and PDIAxxA-CxxC were gifts
from J. Weissman (University of California, San Francisco, CA). Purifica-
tion of the proteins was performed as described in Tu et al. (2000).
Purification of yeast Ero1 and mammalian Ero1 
The yeast strain overexpressing yeast Ero1-Myc-His6 (AFY383) was a gift
from C. Kaiser. The yeast strain overexpressing the mammalian Ero1 -
Myc-His6 protein was constructed as follows. The gene encoding Ero1 
was excised from pcDNA3.1-Ero1 -Myc-His6, a gift from R. Sitia (Univer-
sita Vita-Salute San Raffaele, Milan, Italy) by digesting with XbaI and PmeI.
The fragment was ligated between the XbaI and SmaI sites into a yeast
overexpression vector (p416-GALL). Yeast cells containing this constructRetrotranslocation of cholera toxin | Tsai and Rapoport 215
(p416-Ero1 ) were grown overnight and then cultured in YEP Raf/Gal. The
cells were harvested and homogenized in a french press, followed by cen-
trifugation at 5000g to remove unbroken cells. The supernatant was centri-
fuged at 13,000 g for 30 min to collect the membrane fraction which was
lysed in a buffer containing 1% Triton X-100, 5% glycerol, 50 mM Tris-
HCl, pH 7.4, and protease inhibitors. The soluble material was collected
by centrifugation at 100,000 g for 40 min. Affinity purification of the pro-
teins was performed by binding to a Ni-NTA column. After washing with
10 mM imidazole, proteins were eluted with 500 mM imidazole in a buffer
containing 0.1% Triton X-100, 5% glycerol, 50 mM Tris-HCl, pH 7.4
and protease inhibitors. The eluted sample was dialyzed and bound to a 1
ml Hi-Trap Q-Sepharose column (Amersham Biosciences). Bound material
was eluted with a linear 0–1-M potassium acetate gradient. Fractions of
0.5 ml were collected and Ero1 content analyzed by SDS-PAGE and Coo-
massie staining.
Preparation of ER extract
An ER extract was prepared by adding 0.2% digitonin to a suspension of
2.2 equivalents/ l canine microsomes followed by centrifugation. The su-
pernatant fraction represents the ER extract.
Immunodepletion of mammalian Ero1 and PDI
100  l of ER extract derived from dog microsomes were incubated with 10
 l PDI antibodies or 10  l Ero1 /  antibodies overnight at 4 C, followed
by addition of 20  l protein A Sepharose beads. Mock depletion was per-
formed without antibodies.
Thiol modification with maleimide-PEG5000
Isolated A subunit (70 nM) was incubated with 3  M PDI in the presence of
DTT (100 mM), GSSG (100 mM), or GSH (1 mM) for 30 min at 30 C. To
samples incubated in GSH (1 mM), Ero1 was added and incubated for 20
min at 30 C. 1/10 of the samples was precipitated with trichloroacetic acid,
washed with acetone, and resuspended in a buffer containing 2% SDS, 50
mM Tris (pH 7.4), and 5 mM maleimide-PEG5000 (Shearwater). After incu-
bation for 60 min at 30 C, the samples were analyzed by nonreducing SDS-
PAGE and immunoblotted with an antibody directed against PDI.
Toxin transfer assay
Isolated A subunit (70 nM) was incubated with either ER extract, PDI-
depleted extract, or 3  M PDI for 20 min at 30 C. 10 equivalents of proteo-
liposomes (prepared as described in Gorlich and Rapoport [1993]) were
added for 20 min at 30 C. Samples were sedimented for 20 min at 40,000
rpm in a tabletop ultracentrifuge using a TLA 100.4 rotor. The supernatant
and pellet fractions were analyzed in nonreducing SDS-PAGE followed by
immunoblotting. For preparation of protease-treated proteoliposomes, pro-
teinase K-agarose beads were first incubated with solubilized microsomes
for 30 min at room temperature, followed by removal of the protease by
centrifugation. Hydrophobic SM2 beads were subsequently added to the
solubilized microsomes to remove the detergent and allow formation of
vesicles. Trypsin digestion assay, crosslinking assay, and fractionation of
ER extract performed as described in Tsai et al. (2001).
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